Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study
Immunotherapy, with or without chemotherapy, significantly improved clinical outcomes compared to chemotherapy alone in a real-world cohort of patients with advanced NSCLC. While molecular testing rates increased significantly over the study, only a minority of patients underwent PD-L1 testing, while broad molecular profiling was also incomplete, limiting the interpretation of treatment effects. Improvements to guarantee the universal molecular testing of patients with NSCLC are warranted.
Authors
- Nikoleta Pastelli
- Sofia Lampaki
- Dimitris Kugiumtzis (ORCID: https://orcid.org/0000-0002-5337-5688)
- Dionisiοs Spyratos (ORCID: https://orcid.org/0000-0003-2700-3976)
- Anastasios Vagionas
- Κaterina Manika (ORCID: https://orcid.org/0000-0001-9474-0293)
- Elena Fountzilas (ORCID: https://orcid.org/0000-0002-4884-2544)
- Antonios Katsarolis
- Iliana Tapazidou-Spanoudi
Institutions
- University of Rome Tor Vergata (IT)
- Aristotle University of Thessaloniki (GR)
- G. Papanikolaou General Hospital (GR)
- Technological Educational Institute of Eastern Macedonia and Thrace (GR)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-14
- DOI
- https://doi.org/10.3390/cancers18081239
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hellenic Society of Medical Oncology